Psychedelics biotech company Cybin Inc. (NYSE: CYBN) shared progress updates for its two lead clinical development programs: proprietary deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive Disorder (MDD) and proprietary deuterated DMT compound CYB004 for the potential treatment of Generalized Anxiety Disorder (GAD.)
CYB003
Interim findings from the ongoing Phase 1/2a clinical trial showed positive outcomes, including a rapid and short-acting response in participants accompanied by tolerance and no serious adverse events after single oral doses of CYB003 at 1 mg, 3mg, 8mg and 10mg.
Results confirm that the deuterated psilocybin analog holds low variability in plasma levels while being rapidly absorbed, and is capable of producing a psychedelic effect at low doses while maintaining a safe and well-tolerated therapeutic profile with effects being rapidly washed out.
On the other hand, participants administered 8mg and 10mg doses reported meaningful and robust psychedelic effects, achieving a complete mystical experience.
Dosing at Phase 1 has been completed and Phase 2a has begun, with topline results expected from the completed Phase …